Table 1 Study drug formulation and test cohorts
From: Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM)
Study period 1 (treatment A) | Study period 2 (treatment B) | Study period 3 (treatment C) | Study period 4 (treatment D) | |
|---|---|---|---|---|
Product | JOTROLTM (resveratrol) gelcaps | JOTROLTM (resveratrol) gelcaps | JOTROLTM (resveratrol) gelcaps | JOTROLTM (resveratrol) gelcaps |
Treatment code | A | B | C | D |
Strength | 100 mg | 100 mg | 100 mg | 100 mg |
Dosage form | 2 × 100 mg gelcaps | 5 × 100 mg gelcaps | 7 × 100 mg gelcaps | 5 × 100 mg gelcaps |
Dose administered | 200 mg | 500 mg | 700 mg | 500 mg |
Route of administration | Oral; fasting | Oral; fasting | Oral; fasting | Oral; fed |
Inactive ingredients | Polysorbate 80, polysorbate 20, mixed tocopherols concentrate, fractionated coconut oil, triglycerides (medium chain) | |||
Manufacturer | Catalent Pharma Solutions, St Petersburg, FL 33716-1016 | |||